FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083329993> ?p ?o ?g. }

• W2083329993 endingPage "2064" @default.
• W2083329993 startingPage "2059" @default.
• W2083329993 abstract "Bendamustine is a unique cytotoxic agent that has demonstrated efficacy in the treatment of indolent B-cell non-Hodgkin lymphomas (B-NHLs). In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B-NHL or mantle-cell lymphoma (MCL). Patients received bendamustine (120 mg/m(2) ) on days 1-2 of a 21-day cycle, for up to six cycles. The primary endpoint was the overall response rate (ORR) as assessed by an extramural committee according to International Workshop Response Criteria (IWRC). Secondary endpoints included complete response (CR) rate, ORR according to Revised Response Criteria (revised RC), progression-free survival (PFS), and safety. Fifty-eight patients with indolent B-NHL and 11 with MCL were enrolled. By IWRC, bendamustine produced an ORR of 91% (95% confidence interval [CI], 82-97%; 90% and 100% in patients with indolent B-NHL and MCL, respectively), with a CR rate of 67% (95% CI, 54-78%). ORR and CR rates according to revised RC were 93% (95% CI, 84-98%) and 57% (95% CI, 44-68%), respectively. After a median follow-up of 12.6 months, median PFS had not been reached. Estimated PFS rates at 1 year were 70% and 90% among indolent B-NHL and MCL patients, respectively. Bendamustine was generally well tolerated. Reversible myelosuppression, including grade 3/4 leukopenia (65%) and neutropenia (72%), was the most clinically significant toxicity observed. Common non-hematologic toxicities included mild gastrointestinal events and fatigue. These results demonstrate the high efficacy and tolerability of single-agent bendamustine in relapsed patients with indolent B-NHL or MCL histologies." @default.
• W2083329993 created "2016-06-24" @default.
• W2083329993 creator A5000985713 @default.
• W2083329993 creator A5008746762 @default.
• W2083329993 creator A5013112899 @default.
• W2083329993 creator A5013490553 @default.
• W2083329993 creator A5015509689 @default.
• W2083329993 creator A5016541702 @default.
• W2083329993 creator A5021004681 @default.
• W2083329993 creator A5036000764 @default.
• W2083329993 creator A5047640708 @default.
• W2083329993 creator A5053647194 @default.
• W2083329993 creator A5056287200 @default.
• W2083329993 creator A5063243902 @default.
• W2083329993 creator A5069130284 @default.
• W2083329993 creator A5070190663 @default.
• W2083329993 creator A5087363470 @default.
• W2083329993 creator A5088100950 @default.
• W2083329993 date "2010-08-20" @default.
• W2083329993 modified "2023-10-17" @default.
• W2083329993 title "Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma" @default.
• W2083329993 cites W1009164044 @default.
• W2083329993 cites W1912693401 @default.
• W2083329993 cites W1952875380 @default.
• W2083329993 cites W1972550354 @default.
• W2083329993 cites W1976127594 @default.
• W2083329993 cites W2017518118 @default.
• W2083329993 cites W2036333108 @default.
• W2083329993 cites W2076668534 @default.
• W2083329993 cites W2101141816 @default.
• W2083329993 cites W2101939391 @default.
• W2083329993 cites W2120755425 @default.
• W2083329993 cites W2128936398 @default.
• W2083329993 cites W2133201432 @default.
• W2083329993 cites W2142019712 @default.
• W2083329993 cites W2145560894 @default.
• W2083329993 cites W2154643481 @default.
• W2083329993 cites W2168926834 @default.
• W2083329993 cites W2185675708 @default.
• W2083329993 cites W4293203547 @default.
• W2083329993 doi "https://doi.org/10.1111/j.1349-7006.2010.01635.x" @default.
• W2083329993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20626754" @default.
• W2083329993 hasPublicationYear "2010" @default.
• W2083329993 type Work @default.
• W2083329993 sameAs 2083329993 @default.
• W2083329993 citedByCount "58" @default.
• W2083329993 countsByYear W20833299932012 @default.
• W2083329993 countsByYear W20833299932013 @default.
• W2083329993 countsByYear W20833299932014 @default.
• W2083329993 countsByYear W20833299932015 @default.
• W2083329993 countsByYear W20833299932016 @default.
• W2083329993 countsByYear W20833299932017 @default.
• W2083329993 countsByYear W20833299932018 @default.
• W2083329993 countsByYear W20833299932019 @default.
• W2083329993 countsByYear W20833299932020 @default.
• W2083329993 countsByYear W20833299932021 @default.
• W2083329993 countsByYear W20833299932022 @default.
• W2083329993 crossrefType "journal-article" @default.
• W2083329993 hasAuthorship W2083329993A5000985713 @default.
• W2083329993 hasAuthorship W2083329993A5008746762 @default.
• W2083329993 hasAuthorship W2083329993A5013112899 @default.
• W2083329993 hasAuthorship W2083329993A5013490553 @default.
• W2083329993 hasAuthorship W2083329993A5015509689 @default.
• W2083329993 hasAuthorship W2083329993A5016541702 @default.
• W2083329993 hasAuthorship W2083329993A5021004681 @default.
• W2083329993 hasAuthorship W2083329993A5036000764 @default.
• W2083329993 hasAuthorship W2083329993A5047640708 @default.
• W2083329993 hasAuthorship W2083329993A5053647194 @default.
• W2083329993 hasAuthorship W2083329993A5056287200 @default.
• W2083329993 hasAuthorship W2083329993A5063243902 @default.
• W2083329993 hasAuthorship W2083329993A5069130284 @default.
• W2083329993 hasAuthorship W2083329993A5070190663 @default.
• W2083329993 hasAuthorship W2083329993A5087363470 @default.
• W2083329993 hasAuthorship W2083329993A5088100950 @default.
• W2083329993 hasBestOaLocation W20833299931 @default.
• W2083329993 hasConcept C126322002 @default.
• W2083329993 hasConcept C141071460 @default.
• W2083329993 hasConcept C203092338 @default.
• W2083329993 hasConcept C2776694085 @default.
• W2083329993 hasConcept C2777063308 @default.
• W2083329993 hasConcept C2777525834 @default.
• W2083329993 hasConcept C2778850193 @default.
• W2083329993 hasConcept C2779338263 @default.
• W2083329993 hasConcept C2780653079 @default.
• W2083329993 hasConcept C2780873365 @default.
• W2083329993 hasConcept C2781442060 @default.
• W2083329993 hasConcept C31760486 @default.
• W2083329993 hasConcept C535046627 @default.
• W2083329993 hasConcept C71924100 @default.
• W2083329993 hasConcept C90924648 @default.
• W2083329993 hasConceptScore W2083329993C126322002 @default.
• W2083329993 hasConceptScore W2083329993C141071460 @default.
• W2083329993 hasConceptScore W2083329993C203092338 @default.
• W2083329993 hasConceptScore W2083329993C2776694085 @default.
• W2083329993 hasConceptScore W2083329993C2777063308 @default.
• W2083329993 hasConceptScore W2083329993C2777525834 @default.
• W2083329993 hasConceptScore W2083329993C2778850193 @default.
• W2083329993 hasConceptScore W2083329993C2779338263 @default.

• next